SANTA CRUZ BIOTECHNOLOGY, INC.

BRCA2 (I-17): sc-1818



BACKGROUND

In 1990, a breast cancer susceptibility gene designated BRCA1 was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2 (breast cancer 2, early onset), located on chromosome 13q13.1, also confers a high incidence of breast cancer but, unlike BRCA1 does not confer a substantially elevated risk of ovarian cancer. Both BRCA1 and BRCA2 play a role in the maintainance of genome stability, particularly in the homologous recombination pathway for double-strand DNA repair. BRCA2 is regarded as a tumor suppressor gene; tumors with BRCA2 mutations exhibit loss of heterozygosity (LOH) of the wildtype allele. The protein encoded by the BRCA2 gene contains multiple copies of a 70 amino acid motif called the BRC motif. These motifs effect binding to the Rad51 recombinase, which operates in DNA repair.

CHROMOSOMAL LOCATION

Genetic locus: BRCA2 (human) mapping to 13q13.1.

SOURCE

BRCA2 (I-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of BRCA2 of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-1818 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

BRCA2 (I-17) is recommended for detection of BRCA2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

BRCA2 (I-17) is also recommended for detection of BRCA2 in additional species, including canine.

Suitable for use as control antibody for BRCA2 siRNA (h): sc-29825, BRCA2 shRNA Plasmid (h): sc-29825-SH and BRCA2 shRNA (h) Lentiviral Particles: sc-29825-V.


Molecular Weight of BRCA2: 390 kDa.


Positive Controls: HeLa nuclear extract: sc-2120, ZR-75-1 cell lysate: sc-2241 or A-431 whole cell lysate: sc-2201.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941. 4) Immuno-histochemistry: use ImmunoCruz[™]: sc-2053 or ABC: sc-2023 goat IgG Staining Systems.

DATA





BRCA2 (I-17): sc-1818. Western blot analysis of BRCA2 expression in HeLa nuclear extract (\bf{A}) and A-431 whole cell lysate (\bf{B}).

BRCA2 (I-17): sc-1818. Immunofluorescence staining of methanol-fixed HeLa cells showing nuclear localization (**A**). Immunoperoxidase staining of formalin fixed, paraffin-embedded human adrenal gland tissue showing cytoplasmic, membrane and nuclear staining of glandular cells (**B**).

SELECT PRODUCT CITATIONS

- Lemasson, I., et al. 2002. Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-l-infected T cells. J. Biol. Chem. 277: 49459-49465.
- Lin, H.R., et al. 2003. M phase-specific phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation of the BRCA2-P/CAF complex. J. Biol. Chem. 278: 35979-35987.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed Try **BRCA2 (3D12): sc-293185**, our highly recommended monoclonal aternative to BRCA2 (I-17).